Aroa Biosurgery’s Symphony Trial Hits Primary Endpoint in 12-Week Healing Study

Trial Completion Marks Key Milestone

Aroa Biosurgery Limited (ASX:ARX) has announced the completion of its Symphony randomised controlled trial (RCT), a significant step in validating its flagship wound care product. Symphony, a multi-layered skin substitute designed to treat hard-to-heal wounds such as diabetic foot ulcers (DFUs), was tested against standard care in a rigorous clinical setting.

The trial, conducted across multiple centres in the United States, enrolled up to 150 patients with chronic Wagner grade 1 and 2 diabetic foot ulcers. Patients were randomised to receive either the Symphony treatment or standard wound care dressings, with healing progress monitored over a 12-week period.

Positive Preliminary Findings

Preliminary results indicate that the study met its primary endpoint: a higher proportion of diabetic foot ulcers healed within 12 weeks when treated with Symphony compared to standard care. This early read-out suggests Symphony’s potential to improve healing outcomes in a patient population that often faces prolonged and complicated wound recovery.

AROA’s CEO Brian Ward highlighted the importance of these findings, noting that randomised controlled trials represent the gold standard in clinical evidence. He expressed optimism that the full study results, expected to be published in the coming months, will further cement Symphony’s clinical value and support its wider adoption.

Implications for Market and Reimbursement

Beyond clinical validation, the trial’s success is strategically important for Aroa Biosurgery’s commercial ambitions, particularly in the lucrative US market. The company anticipates that the robust clinical data will meet stringent evidence requirements likely to be set by future reimbursement policies, facilitating broader insurance coverage and uptake.

Symphony’s unique composition; combining AROA’s proprietary extracellular matrix technology with high molecular weight hyaluronic acid; positions it as a differentiated solution in the chronic wound care space. With over seven million AROA devices already used globally, this trial outcome could accelerate Symphony’s penetration into complex wound management.

Looking Ahead

While the preliminary data is encouraging, investors and clinicians alike will be watching closely for the final detailed analysis and peer-reviewed publication. These will provide deeper insights into safety, efficacy, and potential patient benefits, shaping Symphony’s trajectory in the competitive wound care market.